Half of children in with treatable mental health disorders in the United States do not get treatment; a small study demonstrated benefit with immunotherapy for glioblastoma; a task force recommends counseling services for new mothers at risk of depression.
Of the 7.7 million children in the United States with a treatable mental health disorder, half do not receive the necessary treatment, according to a study published in JAMA Pediatrics. The study also found that there was significant variation by state, with Alabama, Mississippi, Oklahoma, and Utah having the highest rates of untreated children.A small study demonstrated that giving patients with glioblastoma immunotherapy before surgery helped them live longer than patients who started drugs after the surgery, STAT. While most patients died by the end of the study, the researchers said the results suggest that timing may be an important factor in treating the disease with the class of drugs.As a result of a recommendation from the US Preventive Services Task Force (USPSTF) on Tuesday, women who are pregnant or have just given birth will get coverage for counseling services if they are risk of depression. According to The Wall Street Journal, USPSTF recommended that women receive counseling if they have any risk factors, including a history of depression or anxiety or complications during pregnancy.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More